Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer. In addition, it develops Talazoparib, which is in phase II clinical trials for treatment of germline mutated HER2 normal breast cancer; Pidilizumab that is in phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and MDV4463, which is in phase I clinical trials for the treatment of nonalcoholic steatohepatitis. The company has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. Medivation, Inc. is headquartered in San Francisco, California.
NEW YORK (TheStreet) -- Medivation (MDVN - Get Report) stock is gaining by 4.25% to $62.55 in mid-afternoon trading on Monday, as the drug maker will explore a sale after receiving takeover interest from a number of companies, sources told Reuters.
Sanofi to nominate 8 people to replace Medivation board http://www.cnbc.com/2016/05/13/sanofi-to-nominate-8-people-to-replace-medivation-board.html
Medivation (MDVN) soared 20% after Pfizer (PFE) said it would buy the San Francisco-based biotech in a $14 billion deal. Pfizer expects the Medivation deal to close before the end of the year and add a nickel to EPS in the first full year after consummation. Pfizer shares slipped 0.8% ahead of the open.
I sold my MDVN Jan 2017 42.50 calls in march after I held for months and was down big then got back to brekeven FML
